Register for APTA CSM in Philadelphia by Nov. 4 to save with early bird rates.
By using this site, you are consenting to our use of cookies. To find out more visit our privacy policy.
Includes articles, courses, and CPGs. Unlimited access for APTA members.
Dec 31, 2025/Article
Lucinda Ann "Cindy" Pfalzer passed away on Dec. 6, 2025, at the age of 67. An APTA member for 35 years, Pfalzer demonstrated a lifelong passion for advocating on behalf of clinicians while advancing research and clinical innovation in physical therapy.
Apr 27, 2026/Article
The Centers for Medicare & Medicaid Services has asked all state Medicaid agencies to conduct a "swift revalidation" of certain Medicaid providers identified as high‑risk for fraud, waste, and abuse, while also directing states to develop a broader provider revalidation strategy within 30 days. Although
Sep 1, 2018/Column
Students identify and meet a need. Patients with cancer benefit.
Jul 12, 2021/Test & Measure
The Harris Infant Neuromotor Test (HINT) is a screening tool designed to identify neuromotor or cognitive/behavioral concerns in infants who are healthy or at high risk between the ages of 3 and 12 months.
Apr 5, 2022/Perspective
As a parent and PT, I am glad that our society has moved from trying to "fix" autism or other types of neurological diagnoses.
Feb 10, 2021/Podcast
Two PTs discuss their career journeys and things to consider when pursuing a PhD.
Sep 1, 2017/Column
A veteran's career path began in Afghanistan.
Some of the most exciting advances in physical therapist practice involve emerging digital technologies.
Sep 18, 2023/Open Access
The Research Agenda for Physical Therapy expands on our profession's continued advancement and considers current issues, new innovations, and forward-thinking viewpoints. The research agenda outlines research priorities that are vital to advancing physical therapist practice and the profession. The development
Oct 3, 2025/CPG
This evidence-based care guideline from Cincinnati Children’s Hospital provides recommendations for therapeutic management of pediatric and adolescent joint hypermobility and hypermobility spectrum disorder, including hypermobile Ehlers-Danlos syndrome. It does not address children and adolescents with
